71% of Self-identified Snorers Have Never Consulted a Healthcare Professional
Key findings of the survey of 1,000 people 18 years and older, include:
- 41% of survey participants snore, or know someone who snores
- 74% know snoring is an indicator for OSA
- 54% are aware that OSA is associated with comorbidities such as heart failure, stroke, and diabetes
- Yet 71% of snorers have never consulted a healthcare professional about their snoring
- 58% of snorers do not know which type of healthcare professional to talk to about sleep issues
- 70% of snorers report that they have not been treated
- 74% of snorers interfere with someone else’s sleep and 72% interfere with their own sleep
- 57% of snorers are unaware that it is possible to be tested for OSA at home
- 94% of snorers who have used CPAP identified specific issues and 37% stopped using it
OSA is the recurring collapse of the airway during sleep, resulting in oxygen shortages and abrupt awakenings accompanied by snoring, gasping, or choking. In addition to daytime sleepiness, OSA is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity and type 2 diabetes. Patients with untreated OSA are 23 times more likely to suffer a heart attack and four times more likely to have a stroke. It is estimated that more than one billion people worldwide and over 74 million people in
“Inaction among snorers, despite strong awareness that snoring is linked with OSA and comorbidities, is one of the novel and alarming findings from this survey. The survey results indicate that snorers do not know which type of medical practitioner to consult and have trepidations about the testing and treatment options presented to them,” said
“Obstructive Sleep Apnea treatment is one of the largest healthcare challenges and medtech business opportunities,” said
The online survey was conducted from
More information about OSA and health risks associated with it is available at www.KnowMoreOSA.com.
ProSomnus (NASDAQ: OSA) is a leading CPAP alternative for the treatment of Obstructive Sleep Apnea, a serious medical disease affecting over 1 billion people worldwide, that is associated with comorbidities including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each patient. Non-invasive, patient preferred and easy to use, ProSomnus devices have demonstrated excellent efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations. ProSomnus precision intraoral devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, TRICARE and many Government sponsored healthcare plans around the world, representing over 200 million covered lives. To learn more, visit www.ProSomnus.com.
Source: ProSomnus Sleep Technologies, Inc.